Skip to main content
NCBI home page
Canadian Journal of Public Health = Revue Canadienne de Santé Publique logoLink to Canadian Journal of Public Health = Revue Canadienne de Santé Publique
. 2000 Jul 1;91(Suppl 1):S24–S28. doi: 10.1007/BF03405103

Treatment Options in Patients with Chronic Hepatitis C

Options de traitement pour les patients atteints d’hépatite C chronique

Kelly W Burak 15, Samuel S Lee 15,✉
PMCID: PMC6979812

Abstract

Hepatitis C is a major health care problem plagued by the lack of a truly effective therapy. To date, the combination of interferon and ribavirin has provided the best chance of viral eradication. However, this therapy is expensive, has multiple side effects and works in less than half of patients. New strategies need to be developed to deal with the increasing burden of hepatitis C-related disease, and we anxiously await the arrival of new drugs such as helicase and protease inhibitors.

Electronic Supplementary Material

Supplementary material is available for this article at 10.1007/BF03405103 and is accessible for authorized users.

French language version/Version en Français

41997_2000_BF03405103_MOESM1_ESM.pdf (118.9KB, pdf)

Options de traitement pour les patients atteints d’hépatite C chronique

Références

  • 1.Marcellin P. Hepatitis C: The clinical spectrum of the disease. J Hepatol. 1999;31(Suppl1):9–16. doi: 10.1016/s0168-8278(99)80368-7. [DOI] [PubMed] [Google Scholar]
  • 2.Sherman M. Management of viral hepatitis: Clinical and public health perspectives - a consensus statement. CASL Hepatitis Consensus Group. Association canadienne pour l’étude du foie. Can J Gastroenterol. 1997;11:407–16. doi: 10.1155/1997/454278. [DOI] [PubMed] [Google Scholar]
  • 3.National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C Hepatology. 1997;23(3Suppl1):2S–10S. doi: 10.1002/hep.510260701. [DOI] [PubMed] [Google Scholar]
  • 4.Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology. 1996;24(4):778–89. doi: 10.1002/hep.510240405. [DOI] [PubMed] [Google Scholar]
  • 5.Carithers RL, Emerson SS. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26(3Suppl1):83S–88S. doi: 10.1002/hep.510260715. [DOI] [PubMed] [Google Scholar]
  • 6.Mabee CL, Crippin JS, Lee WM. Review article: Interferon and hepatitis C - factors predicting therapeutic outcome. Aliment Pharmacol Ther. 1998;12(6):509–18. doi: 10.1046/j.1365-2036.1998.00328.x. [DOI] [PubMed] [Google Scholar]
  • 7.Martinot-Peignoux M, Boyer N, Pouteau M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol. 1998;29:214–23. doi: 10.1016/s0168-8278(98)80006-8. [DOI] [PubMed] [Google Scholar]
  • 8.Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology. 1997;113(2):558–66. doi: 10.1053/gast.1997.v113.pm9247476. [DOI] [PubMed] [Google Scholar]
  • 9.Spengler U, Rockstroh JK. Hepatitis C in the patient with human immunodeficiency virus infection. J Hepatol. 1998;29(6):1023–30. doi: 10.1016/s0168-8278(98)80135-9. [DOI] [PubMed] [Google Scholar]
  • 10.Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med. 1997;127:875–81. doi: 10.7326/0003-4819-127-10-199711150-00003. [DOI] [PubMed] [Google Scholar]
  • 11.Sim H, Yim C, Krajden M, Heathcote J. Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2 B. Am J Gastroenterol. 1998;93(1):39–43. doi: 10.1111/j.1572-0241.1998.039_c.x. [DOI] [PubMed] [Google Scholar]
  • 12.Bennett WG, Inouc Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-a 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855–65. doi: 10.7326/0003-4819-127-10-199711150-00001. [DOI] [PubMed] [Google Scholar]
  • 13.Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-a therapy for chronic hepatitis C. Ann Intern Med. 1997;127:866–74. doi: 10.7326/0003-4819-127-10-199711150-00002. [DOI] [PubMed] [Google Scholar]
  • 14.Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999;29(1):264–70. doi: 10.1002/hep.510290124. [DOI] [PubMed] [Google Scholar]
  • 15.Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24:141–47. doi: 10.1016/s0168-8278(96)80022-5. [DOI] [PubMed] [Google Scholar]
  • 16.Ajello A, Freni MA, Spadaro A, et al. Ten year follow-up of patients with chronic hepatitis C treated with interferon. Hepatogastroenterology. 1999;46(28):2447–50. [PubMed] [Google Scholar]
  • 17.Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhot-ic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131(3):174–81. doi: 10.7326/0003-4819-131-3-199908030-00003. [DOI] [PubMed] [Google Scholar]
  • 18.Castro A, Suarez D, Inglada L, et al. Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res. 1997;17(1):27–30. doi: 10.1089/jir.1997.17.27. [DOI] [PubMed] [Google Scholar]
  • 19.Barbaro G, Di Lorenzo G, Soldini M, et al. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scand J Gastroenterol. 1999;34(9):928–33. doi: 10.1080/003655299750025426. [DOI] [PubMed] [Google Scholar]
  • 20.Heathcote J. Consensus interferon: A novel interferon for the treatment of hepatitis C. J Vir Hepat. 1998;5(Suppl1):13–18. doi: 10.1046/j.1365-2893.1998.0050s1013.x. [DOI] [PubMed] [Google Scholar]
  • 21.Anderson FH, Zeng L, Yoshida EM, Rock NR. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Can J Gastroenterol. 1997;11(4):294–97. doi: 10.1155/1997/562402. [DOI] [PubMed] [Google Scholar]
  • 22.Zarski JP, Maynard-Mute M, Chousterman S, et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology. 1998;27(3):862–67. doi: 10.1002/hep.510270332. [DOI] [PubMed] [Google Scholar]
  • 23.Fabris P, Tositti G, Negro F, et al. Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients. Aliment Pharmocol Ther. 1999;13(10):1329–34. doi: 10.1046/j.1365-2036.1999.00613.x. [DOI] [PubMed] [Google Scholar]
  • 24.Tsutsumi M, Takada A, Takase S, Sawada M. Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: A pilot study. J Gastroenter Hepatol. 1996;11(11):1006–11. doi: 10.1111/j.1440-1746.1996.tb00022.x. [DOI] [PubMed] [Google Scholar]
  • 25.Komatsu M, Ishii T, Ono T, et al. Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration. Can J Gastroenterol. 1997;11(6):507–11. doi: 10.1155/1997/627297. [DOI] [PubMed] [Google Scholar]
  • 26.Tanaka K, Kondo M, Sakaguchi T, et al. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: Results of a long-term follow-up trial. J Gastroenterol Hepatol. 1996;11(12):1155–60. doi: 10.1111/j.1440-1746.1996.tb01844.x. [DOI] [PubMed] [Google Scholar]
  • 27.Crosignani A, Budillon G, Cimino L, et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: A multicenter placebo-controlled study. Hepatogastroenterology. 1998;45(23):1624–29. [PubMed] [Google Scholar]
  • 28.van Rossum TG, Vulto AG, de Man RA, et al. Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998;12(3):199–205. doi: 10.1046/j.1365-2036.1998.00309.x. [DOI] [PubMed] [Google Scholar]
  • 29.Patrick L. Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments. Altern Med Rev. 1999;4(4):220–38. [PubMed] [Google Scholar]
  • 30.Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial. Hepatology. 1998;27(4):1128–35. doi: 10.1002/hep.510270430. [DOI] [PubMed] [Google Scholar]
  • 31.Moscarella S, Buzzelli G, Romanelli RG, et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: Preliminary results. Liver. 1998;18(5):366–69. doi: 10.1111/j.1600-0676.1998.tb00819.x. [DOI] [PubMed] [Google Scholar]
  • 32.Smith JP. Treatment of chronic hepatitis C with amantidine. Dig Dis Sci. 1997;42(8):1681–87. doi: 10.1023/a:1018857314351. [DOI] [PubMed] [Google Scholar]
  • 33.Tabone M, Ercole E, Zaffino C, et al. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Italian J Gastroenterol Hepatol. 1998;30(6):611–13. [PubMed] [Google Scholar]
  • 34.Fong TL, Fried MW, Clarke-Platt J. A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy. Am J Gastroenterol. 1999;94(4):990–93. doi: 10.1111/j.1572-0241.1999.01001.x. [DOI] [PubMed] [Google Scholar]
  • 35.Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol. 1996;25(5):591–98. doi: 10.1016/s0168-8278(96)80225-x. [DOI] [PubMed] [Google Scholar]
  • 36.Schvarcz R, Yun AB, Sönnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol. 1995;46:43–47. doi: 10.1002/jmv.1890460110. [DOI] [PubMed] [Google Scholar]
  • 37.Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers. J Hepatol. 1997;26:961–66. doi: 10.1016/s0168-8278(97)80103-1. [DOI] [PubMed] [Google Scholar]
  • 38.Reichard O, Norkrons G, Fryden A, et al. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 1998;351:83–87. doi: 10.1016/s0140-6736(97)06088-1. [DOI] [PubMed] [Google Scholar]
  • 39.McHutchison J, Gordon S, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–92. doi: 10.1056/NEJM199811193392101. [DOI] [PubMed] [Google Scholar]
  • 40.Poynard T, Marcellin P, Lee S, et al. Randomized trial of interferon 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426–32. doi: 10.1016/s0140-6736(98)07124-4. [DOI] [PubMed] [Google Scholar]
  • 41.Ware JE, Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology. 1999;39(2):550–55. doi: 10.1002/hep.510300203. [DOI] [PubMed] [Google Scholar]
  • 42.Younossi Z, Singer M, McHutchison J, Shermock K. Cost effectiveness of interferon 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30:1318–24. doi: 10.1002/hep.510300518. [DOI] [PubMed] [Google Scholar]
  • 43.Davis G, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493–99. doi: 10.1056/NEJM199811193392102. [DOI] [PubMed] [Google Scholar]
  • 44.Heathcote J, Keeffe E, Lee S, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology. 1998;27:1136–43. doi: 10.1002/hep.510270431. [DOI] [PubMed] [Google Scholar]
  • 45.Poynard T, McHutchison J, Goodman Z, et al. Is an “A la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology. 2000;31:211–18. doi: 10.1002/hep.510310131. [DOI] [PubMed] [Google Scholar]
  • 46.Xu Z, Hoffman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharma-codynamics following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon a2a (IFN-a2a) to healthy subjects. Hepatology. 1998;28Suppl:702A. [Google Scholar]
  • 47.Shiffman ML, Pockros PJ, Reddy RK, et al. A controlled, randomized, multicenter descending dose phase II trial of pegylated interferon a2a vs standard interferon a2a in patients with chronic hepatitis C. Gastroenterology 1999;116(suppl):A1275.
  • 48.Nakamura H, Ito H, Ogawa H, et al. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Hepatogastroenterology. 1999;46(26):1131–39. [PubMed] [Google Scholar]
  • 49.Brillanti S, Foli M, Di Tomaso M, et al. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Italian J Gastroenterol Hepatol. 1999;31(2):130–34. [PubMed] [Google Scholar]
  • 50.Schalm SW, Brouwer JT, Bekkering FC, van Rossum TGJ. New treatment strategies in non-responder patients with chronic hepatitis C. J Hepatol. 1999;31(Suppl1):184–88. doi: 10.1016/s0168-8278(99)80398-5. [DOI] [PubMed] [Google Scholar]
  • 51.Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 1999;117(5):1164–72. doi: 10.1016/s0016-5085(99)70402-6. [DOI] [PubMed] [Google Scholar]
  • 52.Gish R. Future directions in the treatment of patients with chronic hepatitis C virus infection. Can J Gastroenterol. 1999;13(1):57–62. doi: 10.1155/1999/309272. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Journal of Public Health = Revue Canadienne de Santé Publique are provided here courtesy of Springer

RESOURCES